Dengue Human Infection Models Supporting Drug Development

James Whitehorn,1,3 Vinh Chau Nguyen Van,4 and Cameron P. Simmons2,3,5

1Department of Clinical Research, London School of Hygiene and Tropical Medicine, and 2Centre for Tropical Medicine, Oxford University, United Kingdom; 3Oxford University Clinical Research Unit, Hospital for Tropical Diseases, and 4Directorate, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; and 5Nossal Institute for Global Health and Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia

Dengue is an arboviral infection that represents a major global health burden. There is an unmet need for effective dengue therapeutics to reduce symptoms, duration of illness and incidence of severe complications. Here, we consider the merits of a dengue human infection model (DHIM) for drug development. A DHIM could allow experimentally controlled studies of candidate therapeutics in preselected susceptible volunteers, potentially using smaller sample sizes than trials that recruited patients with dengue in an endemic country. In addition, the DHIM would assist the conduct of intensive pharmacokinetic and basic research investigations and aid in determining optimal drug dosage. Furthermore, a DHIM could help establish proof of concept that chemoprophylaxis against dengue is feasible. The key challenge in developing the DHIM for drug development is to ensure the model reliably replicates the typical clinical and laboratory features of naturally acquired, symptomatic dengue.

Keywords. dengue; human infection model; clinical trial; drug development.

The 4 serotypes of dengue virus (DENV-1 to DENV-4) are the most important arboviral pathogens of humans. The global burden of dengue, recently estimated at approximately 100 million cases per year, remains unchallenged by licensed vaccines or sustainable vector control strategies [1]. The scale of the dengue burden in the endemic countries of Asia and Latin America has a negative economic impact and places a significant clinical burden on often fragile health care systems [2–4].

Dengue is an acute systemic febrile illness that manifests with abrupt onset as an undifferentiated fever that is difficult to distinguish from other infections without laboratory diagnostic tests [1]. Headache, malaise, myalgia, retro-orbital pain are common symptoms in adults [5]. The clinical features differ by age group, with symptoms such as cough, vomiting and abdominal pain more common in children [6]. Leukopenia and thrombocytopenia are common laboratory features.

In most cases, fever and symptoms resolve uneventfully after 3–7 days with no long-term sequelae [1]. In a subset of cases, a transient vascular leakage syndrome develops after 3–4 days of illness, which, when severe, can lead to life-threatening hypovolemic shock (called dengue shock syndrome) and/or hemorrhage [1, 5]. The vascular leak syndrome may be associated with complement activation and a coagulopathy that can contribute to the risk of hemorrhage [7, 8]. Signs of vascular leakage include an increasing hematocrit, microalbuminuria, or the accumulation of fluids at serosal surfaces (eg, pleural effusions) [5].

Supportive care and the careful titration of minimum volumes of parenteral crystalloid fluids to maintain stable cardiac output during the 1–3-day period of vascular permeability are critical elements in dengue case management [5]. Vasopressors are commonly used in cases with prolonged shock. Clinically significant hemorrhage requiring use of blood products is more common in adults than in children [9].

Improvements in the management of severe dengue cases have seen the case mortality rate decline over the last decade in many but not all endemic settings [10–12]. At present there is no validated way of identifying which patients will progress to more severe disease, meaning that health facilities in endemic areas are often
overwhelmed with patients with dengue who require ongoing observation as outpatients or are admitted for inpatient observation.

THE CASES FOR DENGUE THERAPEUTIC AND PROPHYLACTIC AGENTS

Antivirals
A drug that can shorten the duration of illness and reduce the risk of disease progression would be a significant advance for both patients and for overstretched health systems in dengue-endemic countries. An obvious approach is to target virus replication with a small molecule antiviral drug that given early in the course of illness has the potential to shorten the duration of infection. Moreover, because high early DENV viremia levels are a risk factor for the development of more severe disease, an antiviral drug might also reduce the incidence of severe complications [13, 14]. In addition, a drug that reduces the magnitude and duration of viremia has the potential to reduce onward DENV transmission by reducing the length of time an individual patient is infectious to mosquitoes [15]. Alternatives to small molecule antiviral drugs include therapeutic monoclonal antibodies; however, high costs and requirement for parenteral administration are currently barriers to their use.

Disease Modulators
Both host and virus factors are important in influencing the outcome of DENV infection. A range of host factors, such as age, sex, genotype, and flavivirus infection history, influence the disease outcome [10, 16, 17]. Because the manifestations of severe dengue are typically observed in secondary DENV infections and when innate and adaptive immune responses have driven steep declines in viremia levels, it is widely held that the immune system plays an important role in disease pathogenesis [18]. This represents the rationale for use of an immunomodulatory drug that can favorably modulate the poorly defined immunopathogenic mechanisms postulated to underlie severe dengue. It is possible that the dichotomous approach of targeting either the virus or the immune response is an oversimplified strategy to the development of dengue therapeutics. Other physiological systems are involved in the control of endothelial integrity, but their role in dengue remains poorly understood [19].

Prophylaxis
A vaccine would be the most effective prophylactic public health intervention for control of dengue, but the development of an efficacious tetravalent dengue vaccine is proving to be a challenge [20, 21]. An alternative or adjunctive approach is the use of drug chemoprophylaxis in the community. Chemoprophylaxis using oseltamivir has been advocated for controlling the spread of influenza within households and was commonly used in some settings during the 2009 H1N1 influenza pandemic, creating a precedent for such an approach for an acute viral infection [22, 23]. The safety profile of a prophylactic dengue drug would have to be exemplary, and there are major questions of whether this approach could be cost-effective and sustainable, given the temporally and spatially heterogenous patterns of DENV transmission in endemic regions [24, 25]. Moreover, in most dengue-endemic regions a significant fraction of the population is already immune and will not benefit from chemoprophylaxis. Consequently, in endemic areas the number needed to treat, and the duration they need to be treated for, may be large for the prevention of a single symptomatic case and very large for the prevention of severe cases. There is a marginally stronger argument for chemoprophylaxis in populations with no immunity to DENV. Examples of this include dengue-naive travelers or military personnel who are transiently present in areas of high DENV transmission. Similarly, chemoprophylaxis could be indicated for communities experiencing "virgin soil" dengue outbreaks because of importation by viremic travelers or infected mosquitoes.

PREVIOUS CLINICAL TRIALS OF THERAPEUTICS FOR DENGUE AND RELEVANCE TO THE DENGUE HUMAN INFECTION MODEL

For a disease with an estimated global burden prevalence of 100 million cases per year, remarkably few clinical trials of treatment approaches have been performed. Early trials tested fluid resuscitation approaches in patients with hypovolemic shock [26–28]. More-recent trials have tested the candidate antiviral agents chloroquine and balapiravir or have targeted the immune response by use of oral corticosteroids [29–31]. Although none of these trials have demonstrated therapeutic efficacy, they have provided a framework for the conduct of such trials and has led to the publication of recommendations for a standardized approach to dengue clinical trial design and conduct [15]. In addition, a trial of lovastatin in dengue is currently underway and further trials are planned [15, 32]. The virological findings in these trials, consistent with previous literature, have underscored the need for antiviral therapy to commence early in the course of illness, because illness resolves and patients are no longer infectious to Aedes aegypti mosquitoes by 5–7 days after illness onset [14, 15, 33–35].

POTENTIAL ROLES FOR A HUMAN INFECTION MODEL IN DENGUE DRUG DEVELOPMENT

In principal, a dengue human infection model (DHIM) provides opportunities for fast-tracking dengue drug development, particularly therapeutic and prophylactic antivirals. The overall strength of the DHIM is that it allows for controlled prophylactic or therapeutic studies of DENV infection in susceptible participants who have been preselected for a set of desirable
characteristics. In contrast, prophylactic or therapeutic studies of DENV infection in an endemic country population are subject to the vagaries of ethnic diversity of the patient population, fluctuating serotype and genotype prevalence, variable viremia levels, and prior flavivirus infection histories. Collectively, these sources of variation in an endemic country population probably boost the required patient sample size required for detection of therapeutic or clinical safety signals.

**CRITICAL HURDLES FOR A DHIM**

Central to the usefulness of a DHIM is whether it mimics the main features of a symptomatic dengue case. This is a fundamental and critical hurdle in the development of a successful DHIM for use in dengue therapeutic development. Thus, the kinetics of clinical, virological, hematological, and biochemical changes that are typically present in a naturally acquired and clinically uncomplicated adult dengue case should also manifest in the adult DHIM. In the beginning, at least, we assume that the DHIM will involve participants who are flavivirus naive, and thus all experimental infections will be primary infections. In the context of dengue drug development, the characteristics of a symptomatic, naturally acquired DENV infection that a DHIM would need to replicate include acquisition of infection and certain clinical, virological, and laboratory features.

**Acquisition of Infection**

A DHIM could use DENV-infected mosquitoes to elicit infection in human volunteers. Although this approach may be optimal in replicating the natural history of DENV infection because, for
example, the immunoregulatory effects of mosquito saliva would be replicated, it may present additional regulatory and logistical hurdles. Alternatively, a DHIM could use subcutaneous inoculation of laboratory-cultured virus, as used in the challenge experiments by Sun and colleagues [36]. This approach bypasses issues surrounding use of mosquitoes, although it remains to be determined if there are material differences between needle-delivered and mosquito-delivered DENV infection.

Clinical Features
Typical signs and symptoms of dengue that a DHIM would need to replicate in otherwise healthy adults include fever, headache, myalgia, musculoskeletal pain, and nausea or vomiting [37]. Minor hemorrhagic features may occur between days 3 and 6 of illness (eg, petechiae) [37]. Prevention or rapid amelioration of these self-limiting symptoms will be a target of dengue therapeutic drug development. Primary infections in otherwise healthy adults are rarely associated with severe clinical complications, but it would be prudent to exclude the elderly and those with comorbid conditions from the volunteer pool, because these groups are at elevated risk of severe complications [38, 39].

Virological Features
The intrinsic incubation period of DENV infection has been estimated to be between 4–10 days [5]. Work that reanalyzed historical mosquito exposure experiments estimated that the intrinsic incubation period in primary infection was approximately 6 days [40]. The duration of viremia varies by serotype and DENV infection history. The peak viremia level is often not observed in naturally occurring infections because it precedes the time point when patients attend health care facilities, but findings suggest that the peak level occurs later in primary infections as compared to secondary [33]. Studies suggest that primary infections with DENV-1 are associated with a longer viremic period and higher viremia levels [33, 41]. An optimal DHIM would replicate the virological features of a naturally acquired DENV infection to enable confident predictions of therapeutic or prophylactic drug efficacy in the field.

Laboratory Features
A DHIM should elicit thrombocytopenia and leukopenia, both typical features in patients with primary or secondary dengue. In addition, many patients have minor elevations in transaminase and creatine kinase levels [9, 42]. Clotting abnormalities are also often observed in severe cases with elevated activated partial thromboplastin times and reduced levels of fibrinogen; however, these occur less frequently in primary infections [43].

STRENGTHS AND WEAKNESSES OF A DHIM FOR DRUG DEVELOPMENT
The strengths and weaknesses of a DHIM for performing early-phase clinical studies compared to performing such studies in naturally acquired cases in an endemic country are summarized in Table 1. In short, the great advantage of the DHIM for early-phase drug development is the ability to perform controlled prophylactic or early therapeutic studies in a setting amenable to intensive pharmacological and basic research investigations.

FOCUS AREAS IN WHICH THE DHIM COULD SUBSTANTIALLY ADVANCE CLINICAL DRUG DEVELOPMENT
A DHIM that mimics natural infection would be particularly well suited to early-phase studies of chemoprophylaxis and accompanying pharmacokinetic and accompanying pharmacokinetic and pharmacodynamic studies in naturally acquired cases in an endemic country, in which the timing of treatment and infection can be controlled. In contrast, in a dengue-endemic country, early-phase chemoprophylaxis trials would require large and lengthy community-based cohort studies, as has been used to derive evidence for oseltamivir in the chemoprophylaxis of influenza [22]. The DHIM would thus be a more cost-effective and time-efficient route to acquiring proof of concept evidence that chemoprophylaxis for dengue is possible. For a given antiviral drug, a DHIM would also be well-suited for studies that accurately define the therapeutic window in symptomatic cases, since the time of infection, onset of symptoms and treatment will be prospectively documented. In contrast, in endemic countries enrollment of study participants is dependent on patients seeking health care, who will have various durations of illness history at the time of study enrollment. A DHIM can also aid the development of alternative therapeutic approaches, such as immunomodulatory agents. In addition, a DHIM may aid the development of noninvasive physiological monitoring techniques within clinical trials, perhaps through the identification of appropriate physiological measurements that could be used as endpoints [15].

In conclusion, the work of Sun and colleagues [36] has shown that a DHIM is possible. This is a significant advance in the field with the potential to contribute to the development of successful dengue therapeutics and much else. The future use of the DHIM in dengue clinical research will require a significant investment from multiple stakeholders. Its contribution in drug development may aid in the selection of appropriate candidate drugs for further development and assist pharmacokinetic studies. The potential significance of these contributions suggests that investing in a DHIM is both appropriate and timely.

Notes
Financial support. This work was supported by fellowships from the Wellcome Trust of the United Kingdom (grants 097430/Z/11/Z to J.W. and 084368/Z/07/Z to C.P.S.).

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
References

1. Simmons CP, Farrar JJ, Nguyen VV, Wills B. Dengue. N Engl J Med 2012; 366:1423–32.
2. Shepard DS, Doudivanlou L, Halasa Y, Zambrano B, Dayan G. Economic impact of dengue illness in the Americas. Am J Trop Med Hyg 2011; 84:200–7.
3. Shepard DS, Undurraga EA, Lees RS, Halasa Y, Lum LC, Ng CW. Use of multiple data sources to estimate the economic cost of dengue illness in Malaysia. Am J Trop Med Hyg 2012; 87:796–805.
4. Wettstein ZS, Fleming M, Chang AY, et al. Total economic cost and burden of dengue in Nicaragua: 1996–2010. Am J Trop Med Hyg 2012; 87:616–22.
5. WHO. Dengue guidelines for diagnosis, treatment, prevention and control: new edition. Geneva, Switzerland: World Health Organization, 2009.
6. Hanafusa S, Chayasyantha C, Sujirarat D, Khuankhunathid I, Yaguchi ASuzuki T. Clinical features and differences between child and adult dengue infections in Rayong Province, Southeast Thailand. Southeast Asian J Trop Med Public Health 2008; 39:252–9.
7. Bokisch VA, Top FH Jr, Russell PK, Dixon FJ, Muller–Eberhard HJ. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med 1973; 289:996–1000.
8. Wills B, Tran VN, Nguyen TH, et al. Hemostatic changes in Vietnamese children with mild dengue correlate with the severity of vascular leakage rather than bleeding. Am J Trop Med Hyg 2009; 81:638–44.
9. Trung DT, Thao le TT, Dung NM, et al. Clinical features of dengue in a large Vietnamese cohort: intrinsically lower platelet counts and greater risk for bleeding in adults than children. PLoS Negl Trop Dis 2012; 6:e1679.
10. Anders KL, Nguyen NM, Chau NV, et al. Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg 2011; 84:127–34.
11. Lumbiganon P, Kosalaraks P, Thepsuthinmarat K, Sutra S. Dengue mortality in patients under 18 years old: an analysis from the health situation analysis of Thai population in 2010 project. J Med Assoc Thai 2012; 95(Suppl 7):S108–13.
12. Moraes GH, de Fatima Duarte E, Duarte EC. Determinants of mortality from severe dengue in Brazil: a population-based case-control study. Am J Trop Med Hyg 2013; 88:670–6.
13. Library DH, Young PR, Pickering D, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 2002; 186:1165–8.
14. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2–9.
15. Simmons CP, Wolbers M, Nguyen MN, et al. Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials. PLoS Negl Trop Dis 2012; 6:e1752.
16. Kouri GP, Guzman MG, Bravo JR, Triana C. Dengue hemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull World Health Organ 1989; 67:375–80.
17. Khor CC, Chau TN, Pang J, et al. Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. Nat Genet 2011; 43:1139–41.
18. Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006; 19:429–36.
19. Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev Cell 2009; 16:209–21.
20. Halstead SB. Dengue vaccine development: a 75% solution? Lancet 2012; 380:1535–6.
21. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559–67.
22. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189:440–9.
23. Lee VJ, Yap J, Cook AR, et al. Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks. N Engl J Med 2010; 362:2166–74.
24. Cummings DA, Iriyazza RA, Huang NE, et al. Travelling waves in the occurrence of dengue haemorrhagic fever in Thailand. Nature 2004; 427:344–7.
25. Balmaseda A, Standish K, Mercado JC, et al. Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis 2010; 201:5–14.
26. Ngo NT, Cao XT, Kneen R, et al. Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis 2001; 32:204–13.
27. Dung NM, Day NT, Tam DT, et al. Fluid replacement in dengue shock syndrome: a randomized, double-blind comparison of four intravenous-fluid regimens. Clin Infect Dis 1999; 29:787–94.
28. Wills BA, Nguyen MD, Ha TL, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005; 353:877–89.
29. Tricou V, Minh NN, Van TP, et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 2010; 4:e785.
30. Tam DT, Ngoc TV, Tien NT, et al. Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin Infect Dis 2012; 55:1216–24.
31. Nguyen NM, Tran CN, Phung IK, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 2013; 207:1442–50.
32. Whitehorn J, Van Vinh Chau N, Truong NT, et al. Lovastatin for adult patients with dengue: protocol for a randomised controlled trial. Trials 2012; 13:203.
33. Tricou V, Minh NN, Farrar J, Tran HT, Simmons CP. Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue. PLoS Negl Trop Dis 2011; 5:e309.
34. Library DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002; 185:1213–21.
35. Nguyen MN, Duong TH, Trung VT, et al. Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes. Proc Natl Acad Sci U S A 2013; 110:9072–7.
36. Sun W, Eckels KH, Putnak JR, et al. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetavalent dengue vaccines. J Infect Dis 2013; 207:700–8.
37. Kalayanarooj S, Vaughn DW, Nimmannitya S, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997; 176:313–21.
38. Wichmann O, Gascon J, Schunk M, et al. Severe dengue virus infection in travelers: risk factors and laboratory indicators. J Infect Dis 2007; 195:1089–96.
39. Itoha I, Masuda G, Suganuma A, et al. Clinical features of 62 imported cases of dengue fever in Japan. Am J Trop Med Hyg 2006; 75:470–4.
40. Nishiura H, Halstead SB. Natural history of dengue virus (DENV)-1 and DENV-4 infections: reanalysis of classic studies. J Infect Dis 2009; 199:1007–13.
41. Duyen HT, Ngoc TV, Ha do T, et al. Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status. J Infect Dis 2011; 203:1292–300.
42. Trung DT, Thao le TT, Hien TT, et al. Liver involvement associated with dengue infection in adults in Vietnam. Am J Trop Med Hyg 2010; 83:774–80.
43. Wills BA, Oragui EE, Stephens AC, et al. Coagulation abnormalities in dengue hemorrhagic fever: serial investigations in 167 Vietnamese children with dengue shock syndrome. Clin Infect Dis 2002; 35:277–85.
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Whitehorn, J; Vinh, CNV; Simmons, CP

Title:
Dengue Human Infection Models Supporting Drug Development

Date:
2014-06-15

Citation:
Whitehorn, J; Vinh, CNV; Simmons, CP, Dengue Human Infection Models Supporting Drug Development, JOURNAL OF INFECTIOUS DISEASES, 2014, 209 pp. 566 - 570

Persistent Link:
http://hdl.handle.net/11343/56680

File Description:
Published version